Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Change in Account Payables (2019 - 2025)

Addex Therapeutics' Change in Account Payables history spans 7 years, with the latest figure at -$185.3 billion for Q2 2025.

  • On a quarterly basis, Change in Account Payables rose 82.01% to -$185.3 billion in Q2 2025 year-over-year; TTM through Jun 2025 was -$28.1 billion, a 104.18% decrease, with the full-year FY2025 number at $471878.5, up 136.07% from a year prior.
  • Change in Account Payables came in at -$185.3 billion for Q2 2025, down from $170.6 billion in the prior quarter.
  • The five-year high for Change in Account Payables was $1411.3 billion in Q4 2023, with the low at -$1224.9 billion in Q3 2024.
  • Historically, Change in Account Payables has averaged $796.0 million across 5 years, with a median of -$154425.5 in 2022.
  • Biggest five-year swings in Change in Account Payables: tumbled 246610803.76% in 2023 and later surged 18946372486.98% in 2024.
  • Year by year, Change in Account Payables stood at $476259.1 in 2021, then tumbled by 272.42% to -$821184.3 in 2022, then surged by 171865410.82% to $1411.3 billion in 2023, then decreased by 14.16% to $1211.5 billion in 2024, then crashed by 115.29% to -$185.3 billion in 2025.
  • Business Quant data shows Change in Account Payables for ADXN at -$185.3 billion in Q2 2025, $170.6 billion in Q1 2025, and $1211.5 billion in Q4 2024.